LV15201B - Ibrutiniba izejvielas iegūšanas paņēmiens - Google Patents

Ibrutiniba izejvielas iegūšanas paņēmiens Download PDF

Info

Publication number
LV15201B
LV15201B LVP-15-98A LV150098A LV15201B LV 15201 B LV15201 B LV 15201B LV 150098 A LV150098 A LV 150098A LV 15201 B LV15201 B LV 15201B
Authority
LV
Latvia
Prior art keywords
boc
pgi
cbz
compound
reaction
Prior art date
Application number
LVP-15-98A
Other languages
English (en)
Latvian (lv)
Other versions
LV15201A (lv
Inventor
Antons ĻEBEDEVS
Jurijs PONOMARJOVS
Larisa VARAČEVA
Dmitrijs ČERŅAKS
Aleksandrs ČERNOBROVIJS
Edvards LAVRINOVIČS
Original Assignee
Latvijas Organiskās Sintēzes Institūts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvijas Organiskās Sintēzes Institūts filed Critical Latvijas Organiskās Sintēzes Institūts
Priority to LVP-15-98A priority Critical patent/LV15201B/lv
Priority to CA2987708A priority patent/CA2987708C/fr
Priority to GB1800657.7A priority patent/GB2556535B/en
Priority to PCT/LV2015/000009 priority patent/WO2017039425A1/fr
Publication of LV15201A publication Critical patent/LV15201A/lv
Publication of LV15201B publication Critical patent/LV15201B/lv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LVP-15-98A 2015-08-31 2015-08-31 Ibrutiniba izejvielas iegūšanas paņēmiens LV15201B (lv)

Priority Applications (4)

Application Number Priority Date Filing Date Title
LVP-15-98A LV15201B (lv) 2015-08-31 2015-08-31 Ibrutiniba izejvielas iegūšanas paņēmiens
CA2987708A CA2987708C (fr) 2015-08-31 2015-11-13 Procede de preparation de precurseur d'ibrutinib
GB1800657.7A GB2556535B (en) 2015-08-31 2015-11-13 A method for preparation of ibrutinib precursor
PCT/LV2015/000009 WO2017039425A1 (fr) 2015-08-31 2015-11-13 Procédé de préparation de précurseur d'ibrutinib

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-15-98A LV15201B (lv) 2015-08-31 2015-08-31 Ibrutiniba izejvielas iegūšanas paņēmiens

Publications (2)

Publication Number Publication Date
LV15201A LV15201A (lv) 2017-03-20
LV15201B true LV15201B (lv) 2017-07-20

Family

ID=54754721

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-15-98A LV15201B (lv) 2015-08-31 2015-08-31 Ibrutiniba izejvielas iegūšanas paņēmiens

Country Status (4)

Country Link
CA (1) CA2987708C (fr)
GB (1) GB2556535B (fr)
LV (1) LV15201B (fr)
WO (1) WO2017039425A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107674079B (zh) * 2017-09-27 2019-12-13 黑龙江珍宝岛药业股份有限公司 一种伊布替尼的合成方法
CN113200986A (zh) * 2021-04-29 2021-08-03 湖南华腾制药有限公司 一种伊布替尼中间体的制备方法
CN114940678B (zh) * 2021-09-26 2023-02-07 上海贵之言医药科技有限公司 一种吡唑并嘧啶酯类化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080007621A1 (en) 2006-07-06 2008-01-10 Sbc Knowledge Ventures, Lp System and method of controlling access to an entrance
CA2681756C (fr) 2007-03-28 2015-02-24 Pharmacyclics, Inc. Inhibiteurs de la tyrosine kinase de bruton
CN101917999A (zh) 2007-11-07 2010-12-15 弗尔德里克斯制药股份有限公司 蛋白质运输的调节
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
US9376438B2 (en) * 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
BR112015021856A2 (pt) 2013-03-15 2017-07-18 Janssen Pharmaceutica Nv processos e intermediários para a preparação de um medicamento

Also Published As

Publication number Publication date
CA2987708A1 (fr) 2017-03-09
GB2556535A (en) 2018-05-30
LV15201A (lv) 2017-03-20
GB201800657D0 (en) 2018-02-28
CA2987708C (fr) 2022-08-02
WO2017039425A1 (fr) 2017-03-09
GB2556535B (en) 2020-10-14

Similar Documents

Publication Publication Date Title
JP5735988B2 (ja) ジヒドロピリドフタラジノン誘導体を合成する方法
TWI622591B (zh) 用於製備｛１－（乙基磺醯基）－３－［４－７Ｈ－吡咯并［２，３－ｄ］嘧啶－４－基）－１Ｈ－吡唑－１－基］吖丁啶－３－基｝乙腈之方法及中間物
EP3712140A1 (fr) Composés contenant un hétéroatome quaternaire
JP6986653B2 (ja) ケトヘキソキナーゼ阻害剤としての二置換ピラゾール化合物
EP2035395A2 (fr) Nouveaux procédés de synthèse d'inhibiteurs de dpp iv
CA3167093A1 (fr) Forme cristalline c du monochlorhydrate de benzamide a fonction 3-(imidazo[1,2-b]pyridazine-3-ylethynyl)-4-methyle-n-{4-[(4-methylpiperazine-1-yl)methyle)3(trifluoromethyle)phenyle}
HUE030836T2 (en) Pyrazine Derivatives As CB2 Receptor Agonists
Chang et al. Parallel synthesis of natural product-like polyhydroxylated pyrrolidine and piperidine alkaloids
LV15201B (lv) Ibrutiniba izejvielas iegūšanas paņēmiens
Boukis et al. Synthesis of structurally diverse 3, 4-dihydropyrimidin-2 (1H)-ones via sequential Biginelli and Passerini reactions
Borah et al. Ir (iii)-Catalyzed [4+ 2] cyclization of azobenzene and diazotized Meldrum's acid for the synthesis of cinnolin-3 (2 H)-one
US20090111991A1 (en) Coupling Process For Preparing Quinolone Intermediates
EA032301B1 (ru) Изоиндолиновые или изохинолиновые соединения, способ их получения и содержащие их фармацевтические композиции
Gupton et al. The application of vinylogous iminium salt derivatives to a regiocontrolled and efficient relay synthesis of lukianol A and related marine natural products
JPH11511487A (ja) インドリルマレイミドの合成
EP1882685A1 (fr) Procede de production d un compose contenant un atome de carbone asymetrique tetrasubstitue
FR2933701A1 (fr) Derives anticancereux, leur preparation et leur application en therapeutique
EP2050735A1 (fr) Méthode de production d'un composé 3-amino-azoté optiquement actif
CN102216267A (zh) 氨基乙酰基吡咯烷甲腈衍生物的纯化方法及其盐
CN111051289A (zh) 被保护的l-肌肽衍生物、l-肌肽以及结晶性l-肌肽锌络合物的制造方法
Romaniszyn et al. Asymmetric vinylogous Michael addition of 5-substituted-furan-2 (3 H)-ones to an α, β-unsaturated-γ-lactam
Solanki et al. Investigation on polymorphs of apixaban, an anticoagulant drug: study of phase transformations and designing efficient process for their preparation
Chan et al. Pyrrolidinones derived from (S)-pyroglutamic acid. Part 3. β-Aminopyrrolidinones
Delarue-Cochin et al. Synthesis of new aza-analogs of staurosporine, K-252a and rebeccamycin by nucleophilic opening of C 2-symmetric bis-aziridines
AU2018201013B2 (en) Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride